Sandoz, a Novartis (NVS) unit, said Monday that the US Supreme Court has denied its petition to review the Federal Circuit's July 2020 decision concerning the Sandoz biosimilar Erelzi or etanercept-szzs for reference medicine Enbrel or etanercept. The Federal Circuit previously ruled against Sandoz in a divided decision upholding Amgen's patents.
Sandoz said it is disappointed the Supreme Court decided not to review its case. The decision means Erelzi, a more affordable biosimilar, will not be available to US patients with autoimmune and inflammatory diseases until 2029. However, the company remains committed to providing important treatment options for patients affected by these diseases.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com